Health officials have confirmed three cases of a new, more dangerous strain of mpox in California, raising concerns about its ...

RAPT Therapeutics, Inc. ( NASDAQ: RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous Urticaria October 20, 2025 8:30 AM EDT Good morning, and welcome to RAPT's conference ...

Mizuho initiated coverage of Celldex (CLDX) with an Outperform rating and $48 price target The firm sees barzolvolimab as positioned to play a ...

RAPT Therapeutics ( ($RAPT) ) just unveiled an update. On October 20, 2025, RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Co., Ltd.

The 3 recent cases are unrelated, but the fact that all 3 people had not traveled internationally indicates that local person ...

Investing.com -- RAPT Therapeutics Inc (NASDAQ:RAPT) stock surged 56.3% in premarket trading Monday following the announcement of positive topline data from a Phase 2 trial of its RPT904 treatment for ...

Rapt Therapeutics said a mid-stage trial of its drug for chronic spontaneous urticaria, a skin condition that causes recurrent, spontaneous hives, showed comparable efficacy and safety to omalizumab, ...

Two cases of a potentially more severe strain of mpox have been confirmed in Los Angeles County. It's the first time this ...

RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with ...

Health officials in Los Angeles County said on Friday they are investigating a possible local spread of a more severe strain ...

Health officials in Long Beach and Los Angeles County have identified three unrelated cases of clade I mpox in Californians ...

Health authorities warn of a severe strain of mpox spreading in parts of California in the United States. While cases remain ...